Cisplatin has been the backbone of the treatment of patients with squamous cell carcinoma of the head and neck, both in recurrent/metastatic settings and in patients with locoregional disease. In patients with recurrent/metastatic disease and a combined positivity score (CPS) ≥20, cisplatin can be replaced by pembrolizumab. In patients with locoregional disease and treated with definitive chemoradiation or in the adjuvant setting, the 3-weekly high-dose cisplatin can be replaced by the weekly 40 mg/m2 cisplatin regimen.

(Belg J Med Oncol 2023;17(2):52–7)